Trials / Completed
CompletedNCT01167023
Prasugrel Versus Placebo in Adult Sickle Cell Disease
A Double-Blind, Randomized, Multicenter Study of Prasugrel Compared to Placebo in Adult Patients With Sickle Cell Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to assess the safety of Prasugrel in adult patients with sickle cell disease (SCD) by monitoring the rate and severity of hemorrhagic events requiring medical intervention compared to placebo for 30 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Prasugrel | Administered orally, once daily for 30 days. |
| DRUG | Placebo | Administered orally, once daily for 30 days. |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2011-06-01
- Completion
- 2011-06-01
- First posted
- 2010-07-21
- Last updated
- 2012-05-03
- Results posted
- 2012-05-03
Locations
14 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01167023. Inclusion in this directory is not an endorsement.